Leuk Lymphoma:评估G6PD活性有助于识别高风险IFD的AML患者

2017-08-14 吴刚 环球医学

侵袭性真菌病(IFD)仍然是急性髓性白血病(AML)患者死亡率和发病率的首要原因。2017年11月,发表在《Leuk Lymphoma》的一项研究表明,评估葡萄糖-6-磷酸脱氢酶活性将有助于识别处于较高IFD风险的AML患者,从而设计更强化的监测和治疗策略。



侵袭性真菌病(IFD)仍然是急性髓性白血病(AML)患者死亡率和发病率的首要原因。2017年11月,发表在《Leuk Lymphoma》的一项研究表明,评估葡萄糖-6-磷酸脱氢酶活性将有助于识别处于较高IFD风险的AML患者,从而设计更强化的监测和治疗策略。

葡萄糖-6-磷酸脱氢酶(G6PD)是一种可以产生NADPH的酶,可以摧毁白细胞呼吸爆发反应中的微生物。研究人员评估了108例进行强化化疗的AML患者中,G6PD缺乏症在IFD敏感性中的作用。

总计,28例患者G6PD缺乏(G6PD-),80例正常(G6PD+)。与G6PD+相比,IFD发病率在G6PD-中显着性高(35.7% vs 5%;P=0.0002;OR,10;95% CI,2.96~37.5)。G6PD-患者中,观察到较高的霉菌感染(17.9% vs 5%;P=0.048;OR,4.1;95% CI,1.0~16.6)和念珠菌脓毒症(17.9% vs 0%;P=0.0009;OR,37.68;95% CI,2.0~707.1)风险。评估G6PD活性将有助于识别处于较高IFD风险的AML患者,从而设计更强化的监测和治疗策略。

原始出处:

Sanna M, Caocci G, Ledda A, et al. Glucose-6-phosphate dehydrogenase deficiency and risk of invasive fungal disease in patients with acute myeloid leukemia. Leuk Lymphoma. 2017 Nov;58(11):2558-2564. doi: 10.1080/10428194.2017.1312666. Epub 2017 Apr 12.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=261573, encodeId=3c142615e38d, content=受用了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Nov 15 23:26:40 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862028, encodeId=8a8618620283f, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Thu Jul 05 03:02:00 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689292, encodeId=b51f16892928a, content=<a href='/topic/show?id=1ddd11158fb' target=_blank style='color:#2F92EE;'>#lymphoma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11158, encryptionId=1ddd11158fb, topicName=lymphoma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45ae28785510, createdName=ms5187542471278033, createdTime=Wed Dec 06 12:02:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233546, encodeId=b9d22335466d, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Aug 14 19:57:33 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233520, encodeId=4ce323352010, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Mon Aug 14 18:12:41 CST 2017, time=2017-08-14, status=1, ipAttribution=)]
    2017-11-15 1209e435m98(暂无昵称)

    受用了.谢谢分享!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=261573, encodeId=3c142615e38d, content=受用了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Nov 15 23:26:40 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862028, encodeId=8a8618620283f, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Thu Jul 05 03:02:00 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689292, encodeId=b51f16892928a, content=<a href='/topic/show?id=1ddd11158fb' target=_blank style='color:#2F92EE;'>#lymphoma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11158, encryptionId=1ddd11158fb, topicName=lymphoma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45ae28785510, createdName=ms5187542471278033, createdTime=Wed Dec 06 12:02:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233546, encodeId=b9d22335466d, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Aug 14 19:57:33 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233520, encodeId=4ce323352010, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Mon Aug 14 18:12:41 CST 2017, time=2017-08-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=261573, encodeId=3c142615e38d, content=受用了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Nov 15 23:26:40 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862028, encodeId=8a8618620283f, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Thu Jul 05 03:02:00 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689292, encodeId=b51f16892928a, content=<a href='/topic/show?id=1ddd11158fb' target=_blank style='color:#2F92EE;'>#lymphoma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11158, encryptionId=1ddd11158fb, topicName=lymphoma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45ae28785510, createdName=ms5187542471278033, createdTime=Wed Dec 06 12:02:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233546, encodeId=b9d22335466d, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Aug 14 19:57:33 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233520, encodeId=4ce323352010, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Mon Aug 14 18:12:41 CST 2017, time=2017-08-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=261573, encodeId=3c142615e38d, content=受用了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Nov 15 23:26:40 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862028, encodeId=8a8618620283f, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Thu Jul 05 03:02:00 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689292, encodeId=b51f16892928a, content=<a href='/topic/show?id=1ddd11158fb' target=_blank style='color:#2F92EE;'>#lymphoma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11158, encryptionId=1ddd11158fb, topicName=lymphoma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45ae28785510, createdName=ms5187542471278033, createdTime=Wed Dec 06 12:02:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233546, encodeId=b9d22335466d, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Aug 14 19:57:33 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233520, encodeId=4ce323352010, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Mon Aug 14 18:12:41 CST 2017, time=2017-08-14, status=1, ipAttribution=)]
    2017-08-14 131****1460

    学习了受益匪浅。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=261573, encodeId=3c142615e38d, content=受用了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Nov 15 23:26:40 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862028, encodeId=8a8618620283f, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Thu Jul 05 03:02:00 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689292, encodeId=b51f16892928a, content=<a href='/topic/show?id=1ddd11158fb' target=_blank style='color:#2F92EE;'>#lymphoma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11158, encryptionId=1ddd11158fb, topicName=lymphoma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45ae28785510, createdName=ms5187542471278033, createdTime=Wed Dec 06 12:02:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233546, encodeId=b9d22335466d, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Aug 14 19:57:33 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233520, encodeId=4ce323352010, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Mon Aug 14 18:12:41 CST 2017, time=2017-08-14, status=1, ipAttribution=)]
    2017-08-14 楠博One

    学习谢谢分享

    0

相关资讯

Lancet:对于侵袭性真菌病,Isavuconazole不劣于伏立康唑

Isavuconazole是一种新型的三氮唑具有广谱抗真菌活性。SECURE试验评估了isavuconazole与伏立康唑对于侵袭性真菌病的疗效和安全性。这是一项3阶段,双盲,多中心的全球,比较组研究。通过使用交互式语音的网络响应系统,通过基线地理区域,同种异体造血干细胞移植,以及活性恶性疾病进行分层,来接受isavuconazonium硫酸372mg(前药;相当于200毫克isavuconazo

2013 血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第四次修订版)

侵袭性真菌病(invasive fungal disease,IFD)系指真菌侵入人体,在组织、器官或血液中生长、繁殖,并导致炎症反应及组织损伤的疾病。中国侵袭性真菌感染工作组经反复讨论,并参照欧洲癌症研究和治疗组织/侵袭性真菌感染协作组(EORTC/IFICG)和美国真菌病研究组(MSG)标准、美国抗感染学会(IDSA)指南及欧洲白血病抗感染委员会指南,对我国原有侵袭性真菌感染的诊断标

中国实体器官移植受者侵袭性真菌病临床诊治指南

中华医学会器官移植学分会和中国医师协会器官移植医师分会结合更新的国内外临床证据,并参考2013年中国侵袭性真菌感染工作组的《血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第四次修订版)》、美国感染学会(IDSA)2016年《念珠菌感染临床实践指南》、2010年《隐球菌感染临床实践指南》、2008年《曲霉菌感染临床实践指南》、2014年欧洲临床微生物与感染性疾病学会《实体器官移植受者中侵袭性

血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第四次修订版)解读

侵袭性真菌感染(invasive fungal infection,IFI)是血液病/恶性肿瘤患者主要的感染并发症及致死原因之一。国内外流行病学研究均显示血液病患者侵袭性真菌感染发病率呈现上升趋势,而且IFI的临床确诊困难,延迟治疗又会导致死亡率升高。临床研究显示念珠菌和曲霉菌感染死亡率近40%~50%,严重影响血液病/恶性肿瘤患者的长期生存。中国侵袭性真菌感染工作组参照欧美标准制定了我国侵袭性真